Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer

A Multi-center Phase II Study Evaluating the Efficacy and Tolerance of the Association of Liposomal Doxorubicin and Docetaxel in First Line Chemotherapy in Patients With Metastatic Breast Cancer

Evaluation of safety and efficacy of a treatment associating Pegylated Liposomal Doxorubicin + Docetaxel in patients with metastatic breast cancer

Evaluation of safety and efficacy of a treatment associating Pegylated Liposomal Doxorubicin + Docetaxel in patients with metastatic breast cancer. Patients will receive pyridoxin to prevent cutaneo-mucinous toxicities.

Inclusion Criteria:

• first metastatic chemo line
• presence of measurable or bone lesion
• at least one lesion outside the radiated areas
• can have previously received hormonotherapy, chemotherapy in adjuvant phase, radiotherapy if older than 4 weeks

Exclusion Criteria:

• only local tumoral progression
• symptomatic cerebral metastasis
• neuropathy > NCI-CTC 2
• previous cancer within 10 years _ previous cancer within 10 years